表纸
市场调查报告书

EpiCast Report:慢性淋巴性白血病的流行病学预测

Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

出版商 GlobalData 商品编码 301138
出版日期 内容信息 英文 43 Pages
订单完成后即时交付
价格
Back to Top
EpiCast Report:慢性淋巴性白血病的流行病学预测 Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027
出版日期: 2018年11月20日内容信息: 英文 43 Pages
简介

所谓慢性淋巴性白血病(CLL),是白血球(淋巴球)癌症的一种,带给特定的淋巴球(B细胞)--主要骨髓、血液内集积,对抗感染疾病的细胞--不良影响。CLL在西欧各国是一般白血病形态,年度平均发病率为每10万人口有5.0件(不论年龄)。基本上是老年人发病的疾病,40岁以下的患者比例为10%以下。全球主要6个国家的发病数量,从2013年的37,795件,预计到2023年增加到45,683,其年复合成长率(CAGR)推算为2.09%。还有治疗完毕的患病人数,从2013年的150,800人,到2023年增加到183,165(年复合成长率(CAGR)是2.15%)。

本报告提供全球主要6个国家(美国、法国、德国、义大利、西班牙、英国)的慢性淋巴性白血病(CLL)的发病情形和今后预测相关分析、疾病的特徵(风险要素和主要的共生病症等等)全球各国的趋势、目前患病者的发病情形、今后10年的发病、患病数量的预测值等调查评估,并将其结果依为您概述为以下内容。

第1章 目录

第2章 简介

  • 概要
  • 近日出版的相关调查

第3章 流行病学

  • 疾病的背景
  • 风险要素和共生病症
  • 全世界的趋势
    • 发病数量
    • 存活率:美国、欧洲5个国家的情况
  • 预测手法
    • 利用之信息来源
    • 未利用之信息来源
    • 预测的前提条件与手法:确诊的发病数量
    • 预测的前提条件与手法:确诊的患病人数(今后5年份)
    • 预测的前提条件与手法:诊断时的Rai分类
  • 慢性淋巴性白血病(CLL)的流行病学预测(今后11年份)
    • 确诊的发病数量
    • 确诊的发病数量(各年龄)
    • 确诊的发病数量(性别)
    • 确诊的发病数量(已调整年龄)
    • 确诊的发病数量(诊断时的各Rai分类)
    • 确诊的患病人数:今后5年的预测
  • 议论
    • 流行病学性的预测相关结论
    • 分析的限制
    • 分析的优势

第4章 附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHCER193-18

Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps.

The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed incident cases of CLL. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of CLL in the 7MM to the moderately rising trend in incidence in the 7MM, combined with the changing population demographics in the respective markets.

Scope

  • The Chronic Lymphocytic Leukemia (CLL) Epidemiology Report provides an overview of the risk factors and global trends of CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. The CLL diagnosed incident cases are segmented by Rai stage, modified Rai stage, and Binet stage at diagnosis, as well as high-risk cytogenetics for the 7MM. Additionally, GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of CLL in the 7MM. To forecast the diagnosed incident and diagnosed prevalent cases of CLL in the 7MM, GlobalData epidemiologists used data from nationally representative, population-based studies for the 7MM.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CLL Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
  • Understand magnitude of CLL patient population by stage.

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Chronic Lymphocytic Leukemia: Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources Used 11
    • 3.4.2 Forecast Assumptions and Methods - Population 20
    • 3.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of CLL 20
    • 3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging and Modified Rai Staging) 23
    • 3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging) 23
    • 3.4.6 High-Risk Cytogenetics (11q Deletion, 13q Deletion, 17p Deletion, p53 mutation, CD38, ZAP70 and IGHV [Unmutated]) Among the Diagnosed Incident Cases of CLL 24
    • 3.4.7 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of CLL 26
  • 3.5 Epidemiological Forecast for CLL (2017-2027) 27
    • 3.5.1 Diagnosed Incident Cases of CLL 27
    • 3.5.2 Age-Specific Diagnosed Incident Cases of CLL 29
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of CLL 30
    • 3.5.4 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis 31
    • 3.5.5 Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis 32
    • 3.5.6 Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis 33
    • 3.5.7 Diagnosed Incident Cases of CLL by High-Risk Cytogenetics 34
    • 3.5.8 Diagnosed Prevalent Cases of CLL 35
  • 3.6 Discussion 36
    • 3.6.1 Epidemiological Forecast Insight 36
    • 3.6.2 Limitations of the Analysis 36
    • 3.6.3 Strengths of the Analysis 37

4 Appendix 38

  • 4.1 Bibliography 38
  • 4.2 About the Authors 41
    • 4.2.1 Epidemiologist 41
    • 4.2.2 Reviewers 41
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 42
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 42
  • 4.3 About GlobalData 43
  • 4.4 Contact Us 43
  • 4.5 Disclaimer 43

1.1 List of Tables

  • Table 1: Risk Factors and Comorbid Conditions Associated with CLL 8
  • Table 2: 7MM, Diagnosed Incident Cases of CLL by High-Risk Cytogenetics, Both Sexes, Ages ≥18 Years, N, 2017 34

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 and 2027 5
  • Figure 2: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 and 2027 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Men, Ages ≥18 Years, 2017-2027 9
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Women, Ages ≥18 Years, 2017-2027 10
  • Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL 11
  • Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging and Modified Rai Staging) 12
  • Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 13
  • Figure 8: 7MM, Sources Used, 11q and 13q Deletion Among the Diagnosed Incident Cases of CLL 14
  • Figure 9: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL 15
  • Figure 10: 7MM, Sources Used, TP53 Among the Diagnosed Incident Cases of CLL 16
  • Figure 11: 7MM, Sources Used, CD38 Among the Diagnosed Incident Cases of CLL 17
  • Figure 12: 7MM, Sources Used, ZAP70 Among the Diagnosed Incident Cases of CLL 18
  • Figure 13: 7MM, Sources Used, IGHV (Unmutated) Among the Diagnosed Incident Cases of CLL 19
  • Figure 14: 7MM, Sources Used, Diagnosed Prevalent Cases of CLL 20
  • Figure 15: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 28
  • Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2017 29
  • Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥18 Years, N, 2017 30
  • Figure 18: 7MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 31
  • Figure 19: 7MM, Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 32
  • Figure 20: 7MM, Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 33
  • Figure 21: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 35
Back to Top